ArticleFrontiers in pharmacology2024

The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.

Yuanxun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.